Robert A. Olson, BSc MD FRCPC MSc

---

---

Dr. Olson is the provincial Division Head of Radiation Oncology & Developmental Radiotherapeutics at UBC, overseeing the academic activities of Radiation Oncologists, residents, and fellows at all six BC Cancer centres, working closely with the clinical Provincial Lead of Radiotherapy at BC Cancer.

After initially practicing in Vancouver, Dr. Olson was the first physician hired at BC Cancer—Prince George, where he primarily treats Head and neck, Breast, and palliative cancer patients. He is the Executive Medical Director of the centre. He is proud to work in a small academic community, pushing the boundaries of academic work.

Dr. Olson’s main areas of research include (1) health services delivery research with a focus on improving evidence-based prescribing practices in radiation oncology, (2) collecting patient-reported outcomes and subsequently improving cancer care based on patient’s feedback, and (3) leading clinical trials, with a current focus on investigating stereotactic ablative radiotherapy in the setting of metastatic disease.

---

EDUCATION
• Harvard University: Master of Science in Epidemiology 2010
• University of British Columbia: FRCPC in Radiation Oncology 2010
• University of Calgary: Medical Doctor 2005
• University of Calgary: Bachelor of Science in Cellular Molecular and Microbial Biology 2002

SELECTED PUBLICATIONS

Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexandar A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Mattews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lnd C, Pai H, Valev B, Lefresne S, Tyldesley S. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncology:8(11); 1644-50

Olson R, McLay M, Hamm J, Callaghan. Identification of tobacco-related cancer diagnoses among individuals with psychiatric disorders: a population based, matched cohort study using a competing-risks approach from British Columbia. Curr Oncol 2021; 28(6):4953-60

Olson R, Mathews L, Liu M, Schellenberg D, Mou B, Berrang T, Harrow S, Correa R, Bhat V, Pai H, Mohamed I, Miller S, Schneiders F, Laba J, Wilke D, Senthi S, Louie A, Swaminath A, Chalmers A, Gaede S, Warner A, de G, T, Allan A, Palma D. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 1-3 Oligometastatic Tumors (SABR-COMET-3): Study Protocol for a Randomized Phase III Trial. BMC Cancer 20:380, 2020.

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C, Mulroy L, Lock M, Rodrigues G, Yaremko B, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Warner A, Senan S. Stereotactic ablative radiotherapy versus standard-of-care palliative treatment in patients with oligometastatic cancer (SABR-COMET): a randomized, phase II, open-label trial. The Lancet 2019;393(10185;2051-8)

Olson R, Chan M, Minhas N, Kandola G, Tiwana M, Lefresne S, Halperin R, Schellenberg D, Wai E, Ahmed N, Tyldesley S. Programmatic comparison and dissemination of an audit of single fraction radiotherapy prescribing practices for bone metastases is associated with a meaningful and lasting change in practice on a population level. Int J Radiat Oncol Biol Phys 2018;102(2):325-9.

Olson R, Howard F, Lapointe F, Schellenberg D, Nichol A, Bowering G, Curtis S, Walter A, Brown S, Thompson C, Bergin J, Lomas S, French S, Halperin R, Tyldesley S, Beckham. Provincial development of a patient reported outcome initiative to guide patient care, quality improvement, and research. Healthcare Management Forum 2018; 31(1)13-17

For further information, please visit Dr. Olson’s ResearchGate page.